Loading
A synthetic erythropoietin (epoetin alfa, darbepoetin) used to treat anemia of kidney disease.
ESAs replace the erythropoietin the failing kidney no longer produces, raising hemoglobin in anemia of CKD. Treatment starts after iron stores are adequate (ferritin, TSAT). Targets are individualized (often Hb 10-12 g/dL); overshooting increases thrombosis and cardiovascular risk. Blood pressure may rise during treatment.
Low hemoglobin caused by kidney failure — reduced erythropoietin production, iron deficiency, and inflammation — treated with iron and ESAs.
Anemia secondary to chronic kidney disease, primarily caused by inadequate erythropoietin production by damaged kidneys, managed with ESAs and iron supplementation.
Advertisement
ZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.